New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2013
12:19 EDTVRX, WFT, LUFK, OMPI, FTK, JNJ, BCRX, GEOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as investors await the start of the latest earnings season, which kicks off unofficially after today's close with Alcoa's (AA) report. The averages all fell into negative ground soon after the open and found a level, from which they have been range-bound ever since. With a very quiet economic calendar today and generally depressed expectations for the earnings seasons, the lackluster trading may extend from here until the close... ECONOMIC EVENTS: In the U.S., no major economic data was reported... COMPANY NEWS: General Electric (GE) agreed to acquire Lufkin (LUFK), which supplies products, technology and services to the oil and gas industry, for $3.3B, or $88.50 per share in cash. Lufkin soared over 37% to trade within 50c of the agreed upon per share price at midday, while some of its peers rose as well, including Flotek (FTK) and Weatherford (WFT), which both advanced over 3%. GE shares, meanwhile, slid 0.4%... MAJOR MOVERS: Among the notable gainers was BioCryst (BCRX), which rose 22% amid reports of new bird flu infections in China. BioCryst is developing peramivir, an investigational anti-viral agent to treat influenza. Among the noteworthy losers was Obagi Medical (OMPI), which fell 6% after Merz Pharma withdrew its offer to acquire Obagi in the face of a $24 per share competing offer from Valeant Pharmaceuticals (VRX). Also lower were shares of Johnson & Johnson (JNJ), which slid nearly 2% after JPMorgan lowered it rating on the stock to Neutral from Overweight... INDICES: Near noon, the Dow was down 51.84, or 0.36%, to 14,513.41; the Nasdaq was down 3.11, or 0.10%, to 3,200.75; and the S&P 500 was down 1.63, or 0.10%, to 1,551.65.
News For LUFK;GE;FTK;WFT;BCRX;OMPI;VRX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 14, 2015
07:46 EDTJNJJohnson & Johnson reports Q1 domestic sales up 5.9% to $8.69B
Subscribe for More Information
07:45 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.56, consensus $1.54
Subscribe for More Information
07:35 EDTGEVeracyte and General Electric join to develop genomic diagnosis solutions
Veracyte (VCYT) and GE (GE) announced a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms were not disclosed. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.
07:04 EDTFTKFlotek and Solazyme announce strategic agreements to develop technologies
Flotek Industries (FTK) and Solazyme (SZYM) announced the companies and certain subsidiaries have entered into agreements to globally commercialize Flocapso. In addition, Flotek will market Solazyme's Encapso lubricant - the first commercially available, biodegradable encapsulated lubricant for drilling fluids in certain Middle Eastern markets. Under the Joint Product Development and Marketing Agreement, Flotek and Solazyme will commercialize and market Flocapso, a proprietary formulation combining Flotek's patented Complex nano-Fluid chemistries with Solazyme's proprietary Encapso technology to create an environmentally-conscious, highly effective drilling fluid additive focused on better lubricity and greater stabilization for drilling programs worldwide. Laboratory and commercial testing indicate that the Flocapso additive will allow the use of water-based fluids in wells that previously required more expensive and invasive oil-based products, providing an environmentally superior, more efficient solution to drilling challenges around the globe. Under the Joint Agreement, Flotek and Solazyme will continue the development of the Flocapso chemistries and work cooperatively to market Flocapso worldwide. The companies are currently in an active validation project with a large national oil company in the Middle East and are pursuing commercial applications in both domestic and international markets.
07:04 EDTFTKFlotek, Solazyme announce agreements to commercialize Flocapso
Subscribe for More Information
April 13, 2015
17:10 EDTJNJIBM establishes a Watson Health Cloud
Subscribe for More Information
16:21 EDTJNJOn The Fly: Top stock stories for Monday
Subscribe for More Information
16:01 EDTGEOptions Update; April 13, 2015
Subscribe for More Information
15:38 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
09:34 EDTGEActive equity options trading on open
Subscribe for More Information
07:52 EDTGEBlackstone Mortgage portfolio purchase from GE a win for both, says UBS
Subscribe for More Information
07:03 EDTGEGeneral Electric risk/reward ratio positive, says Bernstein
Subscribe for More Information
06:32 EDTGEReal estate is a big part of Blackstone's business, NY Times says
Subscribe for More Information
06:09 EDTGEGE must prove that industrial business can grow reliably, WSJ reports
Subscribe for More Information
05:49 EDTGEStocks with implied volatility movement; GE SD
Subscribe for More Information
April 12, 2015
14:56 EDTGEGE investors should consider selling, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use